The mechanisms that drive disease have long confounded the medical industry. How much of a part does genetics play? How does the patient’s lifestyle influence his or her risk of developing cancer? What makes one patient respond favorably to a particular treatment, while another suffers severe side effects?
Global Cancer Consortium
Scientists developing one-size-fits-all bioterrorism vaccine
Scientists at the Scripps Research Institute are developing a new method of vaccination that could potentially be used to provide instantaneous protection whether the target is a cancer cell, flu virus, or […]
An unusual source for antibody–based therapeutics
The future of medicine may lie in an unexpected place: within the immune system of a llama. The Wall Street Journal reports that scientists in Brussels are using llamas to develop antibody–based […]
Study Links Smoking to Most Male Cancer Deaths, Not Just those from Lung Cancer
A new study links smoking to a much greater percentage of deaths among men from all types cancer including lung cancer, suggesting that increased tobacco control efforts could save more lives than […]
Top 10 Medical Innovations for 2009
The Cleveland Clinic has unveiled its latest Top 10 Medical Innovations list, highlighting technologies that are expected to have a big impact in 2009. Announced during Cleveland Clinic’s 2008 Medical Innovation Summit,, […]
Insight Dx Prostate Profile: Clarient Launches Gene Expression Test for Prostate Cancer
Clarient has launched a new gene expression diagnostic for prostate cancer, the Insight Dx Prostate Profile (Insight). The test, developed in conjunction with Health Discovery Corp., uses expression values from four genes […]
AngioDynamics: No Growth Expected in 2009
It’s been a roller coaster of a year for AngioDynamics. In the past, I’ve professed my high opinion of the company. I still like ANGO and I think it’s fairly valued, but […]
A Long Time Coming: Electro-Optical Sciences to Announce MelaFind Trial Results
Irvington-NY based Electro-Optical Sciences (EOS), developer of The MelaFind System, a handheld imaging device that detects melanomas at an early stage, announced last week that its pivotal trial sites have closed: all […]
